Issue |
Med Sci (Paris)
Volume 39, Number 5, Mai 2023
|
|
---|---|---|
Page(s) | 469 - 473 | |
Section | Forum | |
DOI | https://doi.org/10.1051/medsci/2023061 | |
Published online | 23 May 2023 |
Séquençage d’ADN, la fin d’un quasi-monopole ?
Chroniques génomiques
End of a near-monopoly on DNA sequencing
Biologiste, généticien et immunologiste, Président d’Aprogène (Association pour la promotion de la Génomique), 13007 Marseille, France
Abstract
DNA sequencing costs have steadily decreased during the last decade, but the dominant technology (short-read sequencing, Illumina) has seen comparatively little competition after an initial flurry. This phase is now over, with serious competition involving both established and new companies as well as the growing importance of long-read sequencing. The hundred-dollar genome is in sight, and this will have a major impact on many fields of biology.
© 2023 médecine/sciences – Inserm
Article publié sous les conditions définies par la licence Creative Commons Attribution License CC-BY (https://creativecommons.org/licenses/by/4.0), qui autorise sans restrictions l'utilisation, la diffusion, et la reproduction sur quelque support que ce soit, sous réserve de citation correcte de la publication originale.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.